Serina Therapeutics, Inc.
SER
$5.70
-$0.15-2.56%
AMEX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -200.00% | -72.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -200.00% | -72.55% | |||
| Cost of Revenue | -2.07% | 51.51% | |||
| Gross Profit | 0.92% | -55.61% | |||
| SG&A Expenses | -41.81% | 25.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.79% | 35.97% | |||
| Operating Income | 23.32% | -37.40% | |||
| Income Before Tax | -298.99% | -73.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -298.99% | -73.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -55.56% | 0.00% | |||
| Net Income | -294.33% | -72.91% | |||
| EBIT | 23.32% | -37.40% | |||
| EBITDA | 23.57% | -37.99% | |||
| EPS Basic | -471.25% | -73.94% | |||
| Normalized Basic EPS | -268.42% | -73.72% | |||
| EPS Diluted | -331.23% | -74.51% | |||
| Normalized Diluted EPS | -304.58% | -74.19% | |||
| Average Basic Shares Outstanding | 109.42% | 3.96% | |||
| Average Diluted Shares Outstanding | 72.41% | 5.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||